An experimental electronic implant could offer a whole new way to treat type 2 diabetes. Rather than relying on insulin or conventional medications, the device uses electricity to convert excess blood sugar into a substance the body can eliminate. In initial tests on diabetic mice, the technology successfully regulated blood sugar levels and also led to weight loss.
This development comes as type 2 diabetes continues to affect increasing numbers of people around the world. Unlike type 1 diabetes, type 2 diabetes is frequently associated with obesity, limited physical activity, and consuming more energy than the body needs over long periods of time.
Insulin injections can help lower blood sugar by allowing muscle cells to absorb glucose from the blood. However, insulin does not eliminate the underlying problem of excess energy. When the body does not use the glucose it absorbs, the excess can eventually be transformed into fat. This helps explain why some people with diabetes continue to gain weight even when they receive treatment.
Researchers led by Martin Fussenegger, professor at the Department of Biosystems Science and Engineering at ETH Zurich in Basel, have developed an implant designed to solve this problem differently. Their findings were published in the journal Science.
A new diabetes treatment powered by electricity
Fussenegger and his colleagues have spent years developing technologies that can control blood sugar levels. Their previous designs used engineered genetic networks, but these systems relied on living cells and other biological materials.
This dependence introduced several complications. Biological components can create challenges regarding immune compatibility, long-term stability, production and regulatory approval.
The researchers have now taken a different approach by creating a catalyst made entirely of inorganic materials. It performs its function without requiring living cells, enzymes or other biological components.
At the heart of the implant is a piece of graphite felt covered in tiny clusters of gold. These gold structures are coated with even smaller platinum particles, creating a specially designed surface that allows for the chemical reaction necessary to process glucose.
The researchers themselves designed this surface at the nanometric scale. According to Fussenegger, the materials also demonstrated excellent biocompatibility in experimental testing, suggesting that they can interact with living tissues without causing significant adverse reactions.
The system includes an electronic controller enclosed in a 3D printed housing. Instead of relying on a conventional wired electrical connection, the implant receives power wirelessly at a frequency of 13.56 MHz. This frequency is allocated internationally for industrial, scientific and medical applications.
How the implant removes excess sugar from the blood
The technology works by converting excess glucose into gluconate, a substance that can be eliminated from the body through urine.
Normally, glucose provides energy to cells. When more glucose is available than the body needs, some of this excess energy can ultimately be stored as fat. By converting some of the glucose into gluconate, the implant prevents that portion from being metabolized and stored in tissues, potentially helping to reduce fat accumulation.
The entire process is designed to happen automatically, in response to changes in blood sugar as they occur.
A conventional glucose sensor, similar to those worn on the upper arm by many people with diabetes, continuously measures tissue glucose concentrations. When levels rise too high, such as after a meal, the sensor communicates via Bluetooth with a smartphone or smartwatch.
The connected device then activates the implant, providing the electrical energy needed for the catalyst to convert glucose into gluconate.
Once glucose levels return to the desired range, the implant automatically shuts down. This feedback system, known as closed-loop control, is intended to prevent blood sugar levels from dropping dangerously.
Blood sugar control and weight loss in diabetic mice
To evaluate the technology, the researchers first conducted a laboratory experiment using a tank containing 5 liters of a nutrient solution containing glucose. This volume is approximately equal to the amount of blood circulating in the adult human body.
The experiment demonstrated that the catalyst could convert glucose in a solution of this size, an important step toward evaluating its potential for medical applications.
The researchers then implanted the system in diabetic mice. The results showed that the device could accurately regulate the animals’ blood sugar levels. The mice also lost weight, suggesting that converting excess glucose rather than allowing it to contribute to fat storage could provide an additional metabolic benefit.
After six weeks of testing, the implant continued to work reliably and was well tolerated by the animals.
“The system operates at very low voltage and our experiments showed no evidence of tissue damage due to electrical or thermal effects,” says Fussenegger.
Although these results are promising, the device has not yet been tested in humans. Further research will be needed to determine whether the technology can work safely and effectively in people with diabetes.
Could electronics transform the future of diabetes treatment?
Fussenegger believes this technology could represent a fundamental change in the way diabetes is managed. Rather than using drugs to influence how the body processes glucose, an electronic device could directly control the amount of glucose available.
“For decades, we have treated diabetes by telling the body how to manage glucose. Now we are showing that we can control glucose directly, using electronics rather than drugs,” he says. “And the catalyst only activates when glucose levels are too high.”
This approach also creates opportunities to connect medical treatments to digital technologies, including the Internet of Things. These are networks of devices that exchange information and automatically respond to changing conditions.
Researchers envision electronically controlled treatments that could be manufactured at scale and integrated into existing digital health systems.
Their next goal is to transform the experimental implant into a medical device suitable for further development and possible clinical testing.
A potential advantage lies in its relatively simple glucose conversion mechanism. Because the catalyst does not rely on cells or enzymes, the researchers believe some of the technical challenges associated with biological treatments might be easier to overcome.
Much of the supporting technology is also already available. The wireless power transmission systems and external electronic controllers are commercially established, meaning the team would not need to develop each component from scratch.
If future studies demonstrate similar benefits in humans, this approach could open the door to a new class of diabetes treatments in which smart electronic devices help directly regulate blood sugar levels, potentially reducing the need for conventional medications.
Gn Health
